Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Pfizer eyes $26B in COVID-19 vaccine sales for the year, with $3.5B already in the bag
Lilly takes variant-busting COVID-19 antibody into the clinic
Lynch: COVID vaccines bringing new customers to CVS stores
BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says
Moderna plans major expansion at Massachusetts manufacturing site to help boost COVID-19 vaccine supply
UPDATED Coronavirus tracker: Pandemic may have led to decrease in mental healthcare, Anthem study finds
COVID-19 tracker: Biden admin shakes up vaccination strategy; CureVac chief criticizes U.S. export controls
Coworker, institutional support helped nurses maintain mental wellbeing during COVID-19 pandemic: survey
Beckman Coulter targets midsized diagnostic labs with automated sample prep hardware launch

Featured Story

Pfizer eyes $26B in COVID-19 vaccine sales for the year, with $3.5B already in the bag

By Fraiser Kansteiner

Pfizer said its COVID-19 vaccine generated $3.5 billion in the first quarter, but that's nothing compared to what the drug giant expects for the full year. By the time 2021 is through, the company could see $26 billion in Comirnaty revenues, Pfizer predicts.

Lilly takes variant-busting COVID-19 antibody into the clinic

By Nick Paul Taylor

Eli Lilly has begun clinical development of an anti-SARS-CoV-2 antibody designed to work against all currently known circulating variants of concern. The action comes weeks after the FDA revoked the single use emergency authorization of Lilly’s first COVID-19 antibody due to the rise of variants.

Lynch: COVID vaccines bringing new customers to CVS stores

By Paige Minemyer

CVS Health is raising its guidance for the year after posting $2.2 billion in profit for the first quarter.

BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says

By Noah Higgins-Dunn

BioNTech and U.S. partner Pfizer will be able to produce nearly 3 billion doses in 2021, higher than a previously estimated 2.5 billion doses, BioNTech CEO Ugur Sahin told the Financial Times.

Moderna plans major expansion at Massachusetts manufacturing site to help boost COVID-19 vaccine supply

By Noah Higgins-Dunn

Moderna will more than double the size of its manufacturing site in Norwood, Massachusetts, to help reach its newly elevated COVID-19 vaccine supply forecasts. The latest renovations will boost the facility's vaccine production by 50%, the biotech said.

UPDATED Coronavirus tracker: Pandemic may have led to decrease in mental healthcare, Anthem study finds

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: Biden admin shakes up vaccination strategy; CureVac chief criticizes U.S. export controls

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Faced with a slowing vaccine rollout in some parts of the country, the Biden administration said it will shake up its distribution plan while also setting a new goal: 70% of Americans inoculated, even partially, by July 4. CureVac's CEO criticized the U.S. for controlling exports of necessary vaccine manufacturing supplies. And more headlines.

Coworker, institutional support helped nurses maintain mental wellbeing during COVID-19 pandemic: survey

By Dave Muoio

Hospitals can play a major role in supporting workforce wellbeing by supplying adequate resources and training during a crisis, according to a survey of nearly 2,500 NYU Langone nurses.

Beckman Coulter targets midsized diagnostic labs with automated sample prep hardware launch

By Conor Hale

The company’s new DxA 5000 Fit aims to automate the work performed in medium-sized labs, which run between about 2,000 and 5,000 tests per day by reducing up to 80% of the mundane steps.

COVID-19 Tracker